PMID- 38151388
OWN - NLM
STAT- MEDLINE
DCOM- 20240301
LR  - 20240410
IS  - 2152-2669 (Electronic)
IS  - 2152-2669 (Linking)
VI  - 24
IP  - 3
DP  - 2024 Mar
TI  - Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell 
      Lymphoma Patients Treated With Epcoritamab.
PG  - e78-e87.e2
LID - S2152-2650(23)02183-3 [pii]
LID - 10.1016/j.clml.2023.11.005 [doi]
AB  - BACKGROUND: Patient-reported outcomes were evaluated in EPCORE NHL-1 in patients 
      with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) treated with 
      epcoritamab monotherapy (NCT03625037). MATERIALS AND METHODS: Adults with R/R 
      CD20(+) LBCL and >/=2 prior systemic antilymphoma therapies, including anti-CD20, 
      completed the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) and 
      EQ-5D-3L. A subgroup of patients provided additional feedback in one-on-one 
      qualitative interviews. FACT-Lym and EQ-5D-3L score changes from baseline (CFB) 
      to cycle 9 or end of treatment were interpreted using published minimally 
      important differences (MID). RESULTS: In total, 157 patients (88.5% with diffuse 
      LBCL) were treated (median age, 64 years). In total, 70.7% had >/=3 prior 
      treatments, 61.1% had primary refractory disease, and 82.8% were refractory to 
      last systemic therapy. FACT-Lym scores exceeded MID thresholds: mean (SD) CFB 
      were 4.4 (15.2), MID 3.0 to 7.0 (FACT-General); 5.9 (7.6), MID 2.9 to 5.4 
      (FACT-Lymphoma subscale); 8.4 (15.2), MID 5.5 to 11.0 (FACT-Trial Outcome Index); 
      10.3 (20.2), MID 6.5 to 11.2 (FACT-Lym total score). EQ-5D-3L index scores, 0.09 
      (0.20), MID 0.08, and EQ-VAS scores, 16.6 (22.8), MID 7.0, improved. In 20 
      qualitative interviews, 88.2% reported symptom improvements; 80.0% were "very 
      satisfied" or "satisfied" with epcoritamab. CONCLUSIONS: R/R LBCL patients 
      reported consistent, clinically meaningful improvements in symptoms and HRQoL and 
      satisfaction with epcoritamab.
CI  - Copyright (c) 2023 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Phillips, Tycel
AU  - Phillips T
AD  - University of Michigan Comprehensive Cancer Center, Ann Arbor, MI. Electronic 
      address: tphillips@coh.org.
FAU - Lugtenburg, Pieternella
AU  - Lugtenburg P
AD  - On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC 
      Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
FAU - Kalsekar, Anupama
AU  - Kalsekar A
AD  - Genmab, Plainsboro, NJ.
FAU - Mutebi, Alex
AU  - Mutebi A
AD  - Genmab, Plainsboro, NJ.
FAU - Wang, Anthony
AU  - Wang A
AD  - AbbVie, North Chicago, IL.
FAU - Blaedel, Julie
AU  - Blaedel J
AD  - Genmab, Plainsboro, NJ.
FAU - Kosa, Katherine
AU  - Kosa K
AD  - RTI Health Solutions, Ann Arbor, MI.
FAU - Martin, Susan
AU  - Martin S
AD  - RTI Health Solutions, Ann Arbor, MI.
FAU - Sacchi, Mariana
AU  - Sacchi M
AD  - Genmab, Plainsboro, NJ.
FAU - Kilavuz, Nurgul
AU  - Kilavuz N
AD  - Genmab, Plainsboro, NJ.
FAU - Thieblemont, Catherine
AU  - Thieblemont C
AD  - Assistance Publique & Hopitaux de Paris (APHP), Hopital Saint-Louis, 
      Hemato-Oncologie, Universite de Paris, Paris, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT03625037
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20231127
PL  - United States
TA  - Clin Lymphoma Myeloma Leuk
JT  - Clinical lymphoma, myeloma & leukemia
JID - 101525386
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Middle Aged
MH  - *Antineoplastic Agents
MH  - Quality of Life
MH  - *Lymphoma, B-Cell
MH  - *Lymphoma
MH  - Patient Reported Outcome Measures
OTO - NOTNLM
OT  - Bispecific antibodies
OT  - EQ-5D-3L
OT  - FACT-Lym
OT  - Health-related quality of life
OT  - Qualitative data
COIS- Disclosure Tycel Phillips: Seattle Genetics, Pharmacyclics, Incyte, Genentech, 
      Bayer, Gilead Sciences, Curis, Kite/Gilead, Celgene, Genmab, TG Therapeutics, ADC 
      Therapeutics: Consulting or Advisory Role; Seattle Genetics, Lymphoma & Myeloma 
      Connect: Honoraria; AbbVie, Pharmacyclics/Janssen, Bayer: Research Funding; The 
      Leukemia & Lymphoma Society: Scholar in Clinical Research; Pieternella 
      Lugtenburg: Takeda, Servier: Research Grants; Celgene, Roche, Takeda, Genmab, 
      AbbVie, Incyte, Regeneron: Advisory Honoraria. Y-mAbs Therapeutics: Consultancy 
      Honoraria; Lilly: Speakers Bureau; Anupama Kalsekar: Employee of Genmab; Alex 
      Mutebi: Employee of Genmab; Anthony Wang: Employee of AbbVie; Julie Blaedel: 
      Employee of Genmab; Katherine Kosa: Employee of RTI Health Solutions who received 
      funding from Genmab for the design, conduct, and analysis of the qualitative 
      interviews; Susan Martin: Employee of RTI Health Solutions who received funding 
      from Genmab for the design, conduct, and analysis of the qualitative interviews; 
      Mariana Sacchi: Employee of Genmab; Nurgul Kilavuz: Employee of Genmab; Catherine 
      Thieblemont: BMS/Celgene, Hospira, Roche: Research Funding; AbbVie, Amgen, 
      BMS/Celgene, Cellectis, Gilead Sciences, Kite, Novartis, Roche: Consultancy; 
      AbbVie, Amgen, Bayer, Cellectis, Gilead Sciences, Incyte, Janssen, Kite, 
      Novartis, Takeda: Honoraria; AbbVie, Amgen, BMS/Celgene, Cellectis, Gilead 
      Sciences, Incyte, Janssen, Kite, Novartis, Roche, Takeda: Membership on an 
      Entity's Board of Directors or Advisory Committees; AbbVie, Amgen, BMS/Celgene, 
      Cellectis, Gilead Sciences, Kite, Novartis, Roche: Travel, Accommodations, 
      Expenses.
EDAT- 2023/12/28 00:42
MHDA- 2024/03/01 06:44
CRDT- 2023/12/27 21:58
PHST- 2023/10/13 00:00 [received]
PHST- 2023/11/21 00:00 [accepted]
PHST- 2024/03/01 06:44 [medline]
PHST- 2023/12/28 00:42 [pubmed]
PHST- 2023/12/27 21:58 [entrez]
AID - S2152-2650(23)02183-3 [pii]
AID - 10.1016/j.clml.2023.11.005 [doi]
PST - ppublish
SO  - Clin Lymphoma Myeloma Leuk. 2024 Mar;24(3):e78-e87.e2. doi: 
      10.1016/j.clml.2023.11.005. Epub 2023 Nov 27.